Believe it or not: how much can we rely on published data on potential drug targets?
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“reports from the pharmaceutical industry (Begley & Ellis, 2012;Prinz et al., 2011) and systematic assessments of replicability in specific fields, such as cancer biology (Errington, Mathur, et al., 2021), spinal cord injury (Steward et al., 2012) and amyotrophic lateral sclerosis (Scott et al., 2008), have reported success rates ranging from 0 to 40%.”
From Estimating the replicability of Brazilian biomedical science (2025) · cites this paper as Prinz et al., 2011
In the citing paper
“These numbers are in a similar range as previous estimates from the biomedical literature (Begley & Ellis, 2012;Errington, Mathur, et al., 2021;Prinz et al., 2011;Scott et al., 2008;Steward et al., 2012).”
From Estimating the replicability of Brazilian biomedical science (2025) · cites this paper as Prinz et al., 2011
In the citing paper
“This may contribute to publication bias, selective reporting, and questionable research practices that reduce the credibility of the published literature 18-25 .”
From Initial evidence of research quality of registered reports compared with the standard publishing model (2021) · cites this paper as [19]
In the citing paper
“Scientists at Bayer have reported that only ~25% of published preclinical studies could be validated to the point at which projects could progress.2”
From Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities (2019) · cites this paper as [2]
In the citing paper
“A team at Bayer HealthCare in Germany last year reported 4 that only about 25% of published preclinical studies could be validated to the point at which projects could continue.”
From Raise standards for preclinical cancer research (2012) · cites this paper as [4]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2019) · CHANCE · doi:10.1080/09332480.2019.1579573 · Cited by 463
What errors do peer reviewers detect, and does training improve their ability to detect them?
Schroter, S., Black, N., Evans, S., Godlee, F., Osorio, L., & Smith, R. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.080062 · Cited by 226
Osherovich, L. Z. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.416 · Cited by 43
Factors Affecting Reproducibility between Genome-Scale siRNA-Based Screens
Barrows, N. J., Sommer, C. L., Garcia-Blanco, M. A., & Pearson, J. L. (2010) · SLAS Discovery · doi:10.1177/1087057110374994 · Cited by 39
McDonald, R. J., Cloft, H. J., & Kallmes, D. F. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0766 · Cited by 31
Nemery, B. (2001) · Occupational and Environmental Medicine · doi:10.1136/oem.58.9.604 · Cited by 23 · cited 1×
“Adding to this problem, many initially rejected papers will subsequently be published in other journals without substantial changes or improvement”
Background
Research works printed but not linked: 2
- Lehrer, J. The truth wears off: is there something wrong with the scientific method? The New Yorker [online], (2010).
- Freeman, D. H. Lies, damned lies, and medical science. The Atlantic [online], (2010).
Cited by
Items 901–1,000 of 1,001
The great debate: Should Osteoarthritis Research Focus on “Mice” or “Men”?
Hunter, D. J., & Little, C. B. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.07.029 · Cited by 13
Reporting of Preclinical Research in Anesthesiology
Eisenach, J. C., Warner, D. S., & Houle, T. T. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001044 · Cited by 12
Chen, X., Lu, B., & Yan, C.-G. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/128645 · Cited by 15
“However, concerns regarding the reproducibility of biomedical and psychological research are increasingly being expressed (Open Science Collaboration, 2015; Ioannidis, 2005; Prinz et al., 2011).”
BackgroundA simple model suggesting economically rational sample-size choice drives irreproducibility
Braganza, O. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229615 · Cited by 12
“Two, now prominent, studies from the pharmaceutical industry suggested reproducibility rates of 11 and 22% [1, 2].”
BackgroundRecommendations to improve use and reporting of statistics in animal experiments
Rowe, A. (2022) · Laboratory Animals · doi:10.1177/00236772221140669 · Cited by 15
“Results must be robust to withstand clinical trials and commercialisation.(29) The standard measure of statistical significance is”
BackgroundApplication of omics and proteomics in fungi
Salih, I. I., Seddiq, S. H., Hashim, S. S., & Dheeb, B. I. (2022) · AIP conference proceedings · doi:10.1063/5.0121901 · Cited by 20
von Kortzfleisch, V. T., & Richter, S. H. (2023) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2023.109992 · Cited by 15
Scharm, M., & Waltemath, D. (2016) · F1000Research · doi:10.12688/f1000research.9379.1 · Cited by 12
Langhof, H., & Strech, D. (2016) · Springer eBooks · doi:10.1007/978-3-662-49916-0_9 · Cited by 14
Williams, M. J., Mullane, K., & Curtis, M. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804725-5.00005-7 · Cited by 13
Schönbrodt, F. D., Maier, M., Heene, M., & Bühner, M. (2018) · Psychologische Rundschau · doi:10.1026/0033-3042/a000386 · Cited by 12
Hernández‐Arteaga, E., & Ågmo, A. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1192213 · Cited by 17
“, 2013) as well as the medical (Prinz et al., 2011) and social sciences (Camerer et al.”
BackgroundAdvancing reproducibility can ease the ‘hard truths’ of synthetic biology
Lux, M. W., Strychalski, E. A., & Vora, G. J. (2023) · Synthetic Biology · doi:10.1093/synbio/ysad014 · Cited by 19
Drug Targets, Target Identification, Validation, and Screening
den Broeck, W. M. M. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00003-1 · Cited by 12
When Are Results Too Good to Be True?
Churchill, G. A. (2014) · Genetics · doi:10.1534/genetics.114.169912 · Cited by 11
“Many published studies appear to beirreproducible (Prinz et al. 2011; Begley and Ellis 2012).”
BackgroundMaugeri‐Saccà, M., Barba, M., Vici, P., Pizzuti, L., Sergi, D., Catenaro, T., Lauro, L. D., Mottolese, M., Santini, D., Milella, M. S., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.004 · Cited by 13
Modern Prometheus: editing the human genome with Crispr-Cas9
Kozubek, J. (2016) · CERN Document Server (European Organization for Nuclear Research) · Cited by 11
Bongard, R. D., Lepley, M. A., Thakur, K., Talipov, M. R., Nayak, J., Jones, R. A., Bohl, C., Sweeney, N. L., Ramchandran, R., Rathore, R., et al. (2017) · BMC Biochemistry · doi:10.1186/s12858-017-0083-3 · Cited by 10
“A study by Amgen scientists of published academic research in oncology found that <50% of published studies could be reproduced [31], with similar results obtained in a report compiled by researchers at Bayer [31, 32].”
ResultReporting in Experimental Philosophy: Current Standards and Recommendations for Future Practice
Polonioli, A., Vega‐Mendoza, M., Blankinship, B., & Carmel, D. (2018) · Review of Philosophy and Psychology · doi:10.1007/s13164-018-0414-3 · Cited by 12
Wieschowski, S., Laser, H., Sena, E. S., Bleich, A., Tolba, R. H., & Strech, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226443 · Cited by 10
Towards Reproducible Bioinformatics: The OpenBio-C Scientific Workflow Environment
Kanterakis, A., Iatraki, G., Pityanou, K., Koumakis, L., Kanakaris, N., Karacapilidis, N. I., & Potamias, G. (2019) · IEEE International Conference on Bioinformatics and Bioengineering (BIBE) · doi:10.1109/bibe.2019.00047 · Cited by 10
“In a relevant investigation, about 92% (11/12) of interviewed researchers could not reproduce results even if the methods presented in the original papers were exactly replicated [4].”
Zucchelli, P., Horak, G., & Skinner, N. (2020) · SLAS TECHNOLOGY · doi:10.1177/2472630320971218 · Cited by 13
Ashar, Y. K., Clark, J., Gunning, F. M., Goldin, P. R., Gross, J. J., & Wager, T. D. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01366-y · Cited by 16
Assessing the validity and reproducibility of genome-scale predictions
Sugden, L. A., Tackett, M., Savva, Y. A., Thompson, W. A., & Lawrence, C. E. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt508 · Cited by 11
“We explain its utility for assessing the reproducibility of validation experiments, and apply it to a genome- scale study of adenosine deaminase acting on RNA (ADAR)-mediated RNA editing in Drosophila.”
MethodSoft windowing application to improve analysis of high-throughput phenotyping data
Haselimashhadi, H., Mason, J., Muñoz‐Fuentes, V., López, F., Babalola, K., Acar, E. F., Kumar, V., White, J. K., Flenniken, A. M., King, R., et al. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz744 · Cited by 10
“There are two known conditions that affect the method: (1) The weight generating function can be”
BackgroundAuthentication of experimental materials: A remedy for the reproducibility crisis?
Li, F., Hu, J., Xie, K., & He, T. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.07.001 · Cited by 11
“According to two reports by Bayer and Amgen published in 2011 and 2012, 64e89% of the socalled “landmark” results could not be reproduced in their pre-clinical validation experiments.(1,2) One plausible explanation for this out of proportion irreproducibility is related to the intricacy of the scientific experiments,…”
ResultBIO Comes Into the Cold to Adopt BRISQ
Simeon‐Dubach, D., & Moore, H. M. (2014) · Biopreservation and Biobanking · doi:10.1089/bio.2014.1241 · Cited by 11
The Power and Promise of Patient-Derived Xenografts of Human Breast Cancer
Lewis, M. T., & Caldas, C. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041329 · Cited by 12
The learning curve of murine subretinal injection among clinically trained ophthalmic surgeons
Huang, P., Narendran, S., Pereira, F., Fukuda, S., Nagasaka, Y., Apicella, I., Yerramothu, P., Marion, K. M., Cai, X., Sadda, S. R., et al. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.3.13 · Cited by 10
Cheng, Y., Kim, M., Chen, Y., & Zhao, Y. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.217574 · Cited by 11
Research Reproducibility as a Survival Analysis
Raff, E. (2021) · Proceedings of the AAAI Conference on Artificial Intelligence · doi:10.1609/aaai.v35i1.16124 · Cited by 15
Evidence-based medicine or statistically manipulated medicine? Are we slaves to the P -value?
Goel, H., Raheja, D., & Nadar, S. K. (2024) · Postgraduate Medical Journal · doi:10.1093/postmj/qgae012 · Cited by 15
Mimicking women’s endocrine milieu in mice for women’s health-related studies
Constantin, C., Matvienko, D., László, C., Scabia, V., Battista, L., Binz, P., Bruce, S. J., & Brisken, C. (2025) · npj Women s Health · doi:10.1038/s44294-025-00060-4 · Cited by 10
Reproducibility in experimentation – the implications for regulatory toxicology
Berry, S. C. (2014) · Toxicology Research · doi:10.1039/c4tx00069b · Cited by 10
Academic–Pharma Drug Discovery Alliances: Seeking Ways to Eliminate the Valley of Death
Hammonds, T. R. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.111 · Cited by 10
Dailey, L. A. (2018) · Journal of Interdisciplinary Nanomedicine · doi:10.1002/jin2.52 · Cited by 10
“effort, only a very small percentage, 20–25%, of published results from major studies on new drug targets could be reconfirmed in their labs (Prinz et al., 2011).”
BackgroundPredictors of Success of Phase II Pediatric Oncology Clinical Trials
Franshaw, L., Tsoli, M., Byrne, J. A., Mayoh, C., Sivarajasingam, S., Norris, M. D., Marshall, G. M., & Ziegler, D. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2017-0666 · Cited by 11
“Negative preclinical results are usually not published, and it has also been proposed that up to 50% of preclinical findings cannot be reproduced [31, 36, 37].”
BackgroundAnimal Study Translation: The Other Reproducibility Challenge
Berridge, B. R. (2021) · ILAR Journal · doi:10.1093/ilar/ilac005 · Cited by 13
Halloran, J. P., Nohouji, N. A., Hafez, M. A., Besier, T. F., Chokhandre, S. K., Elmasry, S. S., Hume, D. R., Imhauser, C. W., Rooks, N. B., Schneider, M., et al. (2022) · Journal of Orthopaedic Research® · doi:10.1002/jor.25358 · Cited by 10
Executable Simulation Model of the Liver
König, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11682-4 · Cited by 9
Reproducibility efforts as a teaching tool: A pilot study
Karathanasis, N., Hwang, D., Heng, V., Abhimannyu, R., Slogoff-Sevilla, P., Buchel, G., Frisbie, V., Li, P., Kryoneriti, D., & Rigoutsos, I. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010615 · Cited by 14
“to 25% reproducibility success rate was reported in Nature in 2011 in cancer research [5].”
BackgroundConnecting academia and industry for innovative drug repurposing in rare diseases: it is worth a try
Fetro, C. (2023) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.06 · Cited by 12
Redrawing the frontiers in the age of post-publication review
Galbraith, D. W. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00198 · Cited by 12
“Prinz et al. (2011) and Begley and Ellis (2012) have provided widely-discussed commentaries concerning the low rate of reproducibility of landmark experiments in preclinical cancer research.”
BackgroundIs There a Role for Publication Consultants and How Should Their Contribution be Recognized?
Kendall, G., Yee, A. S. V., & McCollum, B. (2015) · Science and Engineering Ethics · doi:10.1007/s11948-015-9710-9 · Cited by 10
“Prinz et al. (2011) notes that many pharmaceutical companies have validation programmes before making an investment, but they often find that results in a scientific paper are difficult to reproduce.”
BackgroundQuality assurance mechanisms for the unregulated research environment
Riedl, D. H., & Dunn, M. K. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.06.007 · Cited by 10
Predicting Target and Chemical Druggability
Oprea, T. I., & Hasselgren, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12342-x · Cited by 12
Statistical proof? The problem of irreproducibility
Holmes, S. (2017) · Bulletin of the American Mathematical Society · doi:10.1090/bull/1597 · Cited by 9
Scherz, P. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108593694 · Cited by 12
Brzeszczyńska, J., Brzeszczyński, F. F., Samuel, K., Morgan, K., Morley, S. D., Plevris, J. N., & Hayes, P. C. (2020) · Cells · doi:10.3390/cells9030770 · Cited by 12
“It has been demonstrated that under different experimental conditions and during differentiation, the analysis of HepaRG RT-qPCR data showed a lack of reproducibility and validity as a properly established normalization method had not been applied [13,14].”
Gonadal sex and animal experimentation: Perfection vs. 3R principle?
Bie, P., & Debrabant, B. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13411 · Cited by 12
“Inadequacy of the information provided in scientific articles is not a new phenomenon (4-6), but in recent years, considerable concern has mounted among researchers, funding agencies, editors and publishers (7-18) leading to a drive towards improvements of the value of experimental results, e.”
BackgroundThe Potential of Notebooks for Scientific Publication, Reproducibility and Dissemination
Rowe, F., Maier, G., Arribas‐Bel, D., & Rey, S. J. (2020) · REGION · doi:10.18335/region.v7i3.357 · Cited by 10
Is the replication crisis a base-rate fallacy?
Autzen, B. (2021) · Metamedicine · doi:10.1007/s11017-022-09561-8 · Cited by 9
“For instance, a team at Bayer HealthCare reported that only about 25% of published preclinical studies could be replicated [3].”
BackgroundHow Research Can and Should Inform Public Policy
Pomeroy, C., & Sanfilippo, F. P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800762-4.00018-9 · Cited by 10
How reproducible are the measurements of leaf fluctuating asymmetry?
Kozlov, M. V. (2015) · PeerJ · doi:10.7717/peerj.1027 · Cited by 10
Neelapu, N. R. R., Srimath-Tirumala-Peddinti, R. C. P. K., Nammi, D., & Pasupuleti, A. M. C. (2014) · Infectious Disorders - Drug Targets · doi:10.2174/1871526514666140321110312 · Cited by 10
“[25] rated discrepancies between published and pharma data as mostly reproducible, partly reproducible and not applicable.”
BackgroundNew forms of checks and balances are needed to improve research integrity
Iorns, E. J., & Chong, C. (2014) · F1000Research · doi:10.12688/f1000research.3714.1 · Cited by 10
HandKAchip - Hands-free killing assay on a chip
Lee, K. S., Lee, L. E., & Levine, E. (2016) · Scientific Reports · doi:10.1038/srep35862 · Cited by 11
Le biais de confirmation en recherche
Larivée, S. J., Sénéchal, C., St-Onge, Z., & Sauvé, M.-R. (2019) · Revue de psychoéducation · doi:10.7202/1060013ar · Cited by 37
Evaluation of reproducible and transparent research practices in pulmonology
Smith, C., Nolan, J., Tritz, D., Heavener, T. E., Pelton, J., Cook, K., & Vassar, M. B. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2020.07.001 · Cited by 10
“Recent attempts at reproducing preclinical(14,15) and clinical studies have found that only 25%--61% of studies may be successfully reproduced.(6,16) Within the field of critical care medicine, a recent publication found that only 42% of randomized trials contained a reproduction attempt with half of those reporting i…”
BackgroundResultBig Data in Computational Toxicology: Challenges and Opportunities
Zhao, L., & Zhu, H. (2018) · Wiley eBooks · doi:10.1002/9781119282594.ch11 · Cited by 11
Helliwell, J. R., Minor, W., Weiss, M. S., Garman, E. F., Read, R. J., Newman, J. M., van Raaij, M. J., Hajdu, J., & Baker, E. N. (2019) · IUCrJ · doi:10.1107/s2052252519005918 · Cited by 10
The Australian academic STEMM workplace post-COVID: a picture of disarrayPreprint
Christian, K., Larkins, J., & Doran, M. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.06.519378 · Cited by 12
“, at Bayer, reported only being able to replicate 20-25% of 67 seminal studies [33].”
BackgroundFacilitating transparency in spinal cord injury studies using data standards and ontologies
Lemmon, V., Abeyruwan, S., Visser, U., & Bixby, J. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.125322 · Cited by 9
“They found in 61 internal projects that only 21% of original studies could be replicated (Prinz et al., 2011).”
Replication of null results: Absence of evidence or evidence of absence?
Pawel, S., Heyard, R., Micheloud, C., & Held, L. (2023) · eLife · doi:10.7554/elife.92311 · Cited by 25
“In the last decade, various large-scale replication projects have been conducted in diverse fields, from the biomedical to the social sciences ( Prinz et al., 2011 ; Begley and Ellis, 2012 ; Klein et al., 2014 ; Open Science Collaboration, 2015 ; Camerer et al., 2016 ; Camerer et al., 2018 ; Klein…”
BackgroundData standards in drug discovery: A long way to go
Kelm, J. M., Ferrer, M., Bittner, M.-I., & Lal‐Nag, M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103879 · Cited by 9
Impact and Assessment of Research Integrity Teaching: A Systematic Literature Review
Crean, D., Gordijn, B., & Kearns, A. J. (2024) · Science and Engineering Ethics · doi:10.1007/s11948-024-00493-1 · Cited by 15
“Such practices are leading to problems such as erroneous data and misinformation, and if unresolved may negatively affect society’s trust in science (Altman, 1994; Baker, 2016; Brainard, 2018; Freedman, 2010; Prinz et al., 2011).”
BackgroundRevolutionizing IBD research with on-chip models of disease modeling and drug screening
Yilmaz, E. G., Hacıosmanoğlu, N., Jordi, S. B. U., Yılmaz, B., & İnci, F. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.10.002 · Cited by 10
Overcoming functional and translational challenges of cellular immunotherapies for solid tumors
Chen, Y.-C., Chen, K., Levine, B. L., & Shah, K. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.002 · Cited by 12
Gangwal, A., & Lavecchia, A. (2026) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70072 · Cited by 13
“…a recurrent pattern of claim inflation documented in independent benchmarking and reproducibility studies, where tools labeled as “revolutionary” or “breakthrough” often prove only marginally competitive when tested on external datasets or under clinically realistic conditions [7, 77, 78].”
Kerpel‐Fronius, S., Becker, S., Barrett, J., Brun, J., Carlesi, R. M., Chan, A., Collia, L. F., Dubois, D. J., Kleist, P., Koski, G., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00843 · Cited by 11
“Similarly, from 67 projects evaluated by a company 65% of the results published in the scientific literature could not be reproduced (Prinz et al., 2011).”
BackgroundMinimum Information in In Vivo Research
Voehringer, P., & Nicholson, J. R. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_285 · Cited by 13
“However, it has been described many times over the last few years that in preclinical research – particularly preclinical animal research – many findings presented in high-profile journals are not reliable and cannot be replicated (Begley and Ellis 2012; Peers et al. 2012; Prinz et al. 2011).”
BackgroundFrom viability to cell death: Claims with insufficient evidence in high-impact cell culture studies
Özkaya, A. B., & Geyik, C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0250754 · Cited by 11
“Reproducibility in preclinical research is estimated to be between 10% to 25% [5, 6] and the cost of irreproducible research is calculated to be at least 28 billion USD/year in USA alone [7].”
BackgroundJohnston, I. G., Slater, M. W., & Cazier, J. (2022) · Frontiers in Education · doi:10.3389/feduc.2022.826951 · Cited by 10
“…reproducibility crisis across scientific disciplines (Collaboration et al., 2015) including drug discovery for cancer, where only 11% of pre-clinical research results were found to be reproducible ( Begley and Ellis, 2012), and Phase II success rates had fallen to 18% in 2011 (Prinz et al., 2011).”
BackgroundThe Problem of Irreproducible Bioscience Research
Flier, J. S. (2022) · Perspectives in biology and medicine · doi:10.1353/pbm.2022.0032 · Cited by 12
The erosion of research integrity: the need for culture change
Ellis, L. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00085-6 · Cited by 10
Quality and reporting practices in an Australian cancer biobank cohort
Rush, A., & Byrne, J. A. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.12.007 · Cited by 9
Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays
Langer, G. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_18 · Cited by 12
“In order to cope with these information-rich formats and their increasing technical complexity, cell-based assay development has become a scientific research topic in its own right and is used to ensure the provision of significant, reliable and highquality data outlasting any discussions related to the current “irrep…”
MethodNovel or reproducible: That is the question
Hagen, K. G. T. (2016) · Glycobiology · doi:10.1093/glycob/cww036 · Cited by 12
Science Between Trust and Control: Non-Reproducibility in Scholarly Publishing
Franzen, M. (2016) · John Wiley & Sons, Inc. eBooks · doi:10.1002/9781118865064.ch22 · Cited by 11
Efficient Modulation of TP53 Expression in Human Induced Pluripotent Stem Cells
Uhlmann, C., Kuhn, L. M., Tigges, J., Fritsche, E., & Kahlert, U. D. (2019) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.102 · Cited by 8
Micro- and Macroenvironmental Conditions and Stability of Terrestrial Models
Lee, V. K., David, J. M., & Huerkamp, M. J. (2019) · ILAR Journal · doi:10.1093/ilar/ilaa013 · Cited by 12
Ligand engineering for theranostic applications
Altmann, A., Kratochwil, C., Giesel, F. L., & Haberkorn, U. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.04.006 · Cited by 9
Lost in Translation ( LiT ): IUPHAR Review 6
Dollery, C. T. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12580 · Cited by 11
“Bayer scientists were unable to replicate about two-thirds of published studies identifying drug targets (Prinz et al., 2011).”
BackgroundLate, never or non‐existent: the inaccessibility of preclinical evidence for new drugs
Federico, C. A., Carlisle, B. G., Kimmelman, J., & Fergusson, D. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12771 · Cited by 9
“Other reports describe problems replicating preclinical studies (Prinz et al., 2011; Steward et al., 2012) – a phenomenon that some attribute to selective reporting.”
BackgroundClinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development
Patel, A. C. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113505906 · Cited by 11
Review: Basics of Drug Development in Rheumatology
Mina‐Osorio, P. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39253 · Cited by 9
“reviewed recently (19,20), another major difficulty dur-”
Russo, F., Righelli, D., & Angelini, C. (2016) · Lecture notes in computer science · doi:10.1007/978-3-319-44332-4_19 · Cited by 12
Prinzen, F. W., Dagres, N., Bollmann, A., Arnar, D. O., Bove, S., Camm, A. J., Casadei, B., Kirchhof, P. F., Kück, K., Lumens, J., et al. (2017) · EP Europace · doi:10.1093/europace/eux095 · Cited by 9
How to understand and teach P values: a diagnostic test framework
Baduashvili, A., Evans, A. T., & Cutler, T. S. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.03.003 · Cited by 9
Grahe, J. E., & Cuccolo, K. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009000796.014 · Cited by 9
Paaßen, B., Stöckel, A., Dickfelder, R., Göpfert, J. P., Brazda, N., Kirchhoffer, T., Müller, H. W., Klinger, R., Härtung, M., & Cimiano, P. (2014) · doi:10.3115/v1/w14-6204 · Cited by 9
“…published information by far exceeds the capacity of individual scientists to read and understand the relevant knowledge (Lok, 2010), the selection of promising therapeutic interventions for clinical trials is notoriously based on incomplete information (Prinz et al., 2011; Steward et al., 2012).”
BackgroundKuske, R. R., & Young, S. S. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.12.002 · Cited by 9
Bridging the gap between basic and applied biology: towards preclinical translation
Cagan, R. L., Justice, M. J., & Tidmarsh, G. F. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.012450 · Cited by 9
“Recently, two major pharmaceutical companies, Bayer and Amgen, reported on the lack of reproducibility of published preclinical research (Begley and Ellis, 2012; Prinz et al., 2011).”
BackgroundOpen Science Collaboration (2013) · SSRN Electronic Journal · doi:10.2139/ssrn.2195999 · Cited by 10
Charting the Constellation of Science Reform
Field, S. M. (2022) · Liberate Science GmbH eBooks · doi:10.53962/meeb-2ktd · Cited by 11
Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration
Hastings, L., Sokratian, A., Apicco, D. J., Stanhope, C. M., Smith, L., Hirst, W. D., West, A. B., & Kelly, K. (2022) · Brain Communications · doi:10.1093/braincomms/fcac042 · Cited by 9
“It is generally accepted that inter-laboratory replication of key supporting end-points related to the pre-clinical evaluation of clinical candidate therapeutics represents an important aspect of rigour and reliability in contemporary therapeutic discovery efforts.(28,29) The primary purpose of this study was to repli…”
Karabağ, S. F., Berggren, C., Pielaszkiewicz, J., & Gerdin, B. (2024) · Journal of Academic Ethics · doi:10.1007/s10805-024-09520-z · Cited by 12
“…author information available on the last page of the article low replicability of findings even in top journals (Begley & Ellis, 2012; Camerer Colin et al., 2016; Chalkia et al., 2020; Open Science Collaboration, 2015; Prinz et al., 2011) have brought attention to problems in contemporary science.”
Ahuis, T. P., Smyk, M. K., Laloux, C., Aulehner, K., Bray, J. G., Waldron, A., Miljanovic, N., Seiffert, I., Song, D., Boulanger, B., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309521 · Cited by 10
“For example, Bayer Healthcare Germany reported that in only about 25% of cases a sufficient validation of findings for project continuation is provided [10].”
Taciak, B., Grochowska, A., Górczak, M., Górka, E., Skorzynski, M., Białasek, M., Rygiel, T. P., & Król, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031272 · Cited by 10
Reproducibility of 24-h heart rate variability in children
Bjelakovic, B., Ilic, D., Lukic, S., Vukomanovic, V., Zarko, C., Stankovic, Z., & Marko, J. (2017) · Clinical Autonomic Research · doi:10.1007/s10286-017-0445-3 · Cited by 7
Metadata
- Authors
- Prinz, F., Schlange, T., & Asadullah, K.
- Affiliations
- Bayer (Germany) (DE)
- Corresponding author
- Asadullah, Khusru
- ORCID
- Schlange, Thomas
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-31
- Volume
- 10
- Issue
- 9
- Pages
- 712-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2067833766
- Cited by
- 1,888
- References
- 8
- Citations by year
- 2026: 56 · 2025: 60 · 2024: 86 · 2023: 108 · 2022: 138 · 2021: 126 · 2020: 131 · 2019: 171 · 2018: 147 · 2017: 176 · 2016: 202 · 2015: 183 · 2014: 141 · 2013: 98 · 2012: 57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- therapeutic target, reproducibility, publication bias, false positives, peer review, manuscript rejection, siRNA screen, drug target validation
- MeSH terms
- Drug Industry, Humans, Drug Design, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.